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To determine the relationship between changes in room air 
oxygen saturation (SaO) and changes in the clinical signs of 
pediatric asthma patients after treatment with nebulized albuterol, 
a 9-month prospective observational study was conducted. 
Eighty-two patients from 2 to 15 years of age who had 
exacerbations of asthma were studied when they presented to 
a military community hospital emergency department with an 
annual census of 62,500. 
For each patient, the change in Sa02 30 minutes after admin-istration of nebulized albuterol was compared to the change in 
an ordinal clinical scoring system for asthma. Physicians were 
blinded to Sa02 measurements. Data are reported as mean 
values with differences between groups analyzed using the 
paired t-test. 
Patients with an initial Sa02<95% who clinically improved 
after treatment had a mean increase in their Sa02 of 2.6%. Patients with an initial SaO 2 <95% who did not clinically improve 
after treatment had a mean decrease in Sa02 of 1.1%, but this 
was not statistically significant (p=0.14). The positive predictive 
value for improved Sa02 indicating clinical improvement is 98%. 
Patients with an initial Sa02>95% did not have significant changes 
in Sa02 after treatment regardless of clinical response. 
For pediatric asthma patients with an initial Sa02<95%, in-
creased Sa02 after treatment with inhaled albuterol is predictive 
of clinical improvement. Patients with an initial Sa02<95% who do not have improved Sa02 after treatment require further 
evaluation. 
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Introduction 
Several investigators have used various laboratory methods in 
an attempt to quantitate objectively the degree of respiratory 
distress of patients suffering from acute exacerbations of asthma. 
These studies have included measurements of FEV1, peak-
expiratory flow rates (PEFR), 1 and arterial blood gas concentra-
tions (ABG).2 Unfortunately, these laboratory studies are either 
effort-dependent or painful, and this makes their use with some 
patients, particularly small children, difficult if not impossible 
to perform. 
Pulse oximetry noninvasively measures the percentage of 
hemoglobin bound to oxygen.3 It has become an important tool 
in the evaluation of respiratory function of patients in the 
emergency department. For pediatric patients presenting with 
acute exacerbations of asthma, it can provide an objective means 
of evaluating a patient's degree of respiratory distress. 
Some physicians use serial Sa02 measurements during the 
treatment of acute exacerbations of asthma as a means of 
assessing the response to treatment.4 However, different studies 
have reported both increasing and decreasing Sa02 measure-
ments in response to beta-2 agonists.5-6 These contradictory data 
make the use of Sa02 measurements to assess the response of 
asthmatics to albuterol a questionable practice. 
The purpose of this study is to determine the relationship 
between changes in room air oxygen saturation (Sa02) and 
changes in the clinical signs of pediatric asthma patients after 
treatment with inhaled albuterol. 
Methods and Materials 
All patients from 2 to 15 years of age who presented to the 
emergency department at Darnall Army Community Hospital 
with wheezing secondary to asthma were eligible for enroll-
ment. Data were collected over a 9-month period. Exclusion 
criteria were: 1) the presence of lobar pneumonia, cardiovascu-
lar disease, foreign body aspiration, trauma, cystic fibrosis, or 
sepsis; or 2) severe respiratory compromise necessitating 
intubation before response to nebulized albuterol could be 
assessed. Mild respiratory infections consistent with a viral 
syndrome were not considered exclusionary. The study protocol 
was reviewed and approved by the hospital's institutional re-
view board at Brooke Army Medical Center in San Antonio, 
Texas. Written informed consent was obtained from the legal 
guardians of study participants. 
All of the patients who met our inclusion criteria had an initial 
Sa02 measurement recorded by pulse oximetry (Physio-Control 
Lifestat 1600 Pulse Oximeter). The SaO 2 measurement recorded 
was the highest level observed over a 15 to 30-second period 
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accompanied by a correlating arterial pulse. The initial Sa02 and 
all subsequent measurements were to be recorded by a nurse or 
medic. The physician treating the patient was blinded to these 
readings. 
Prior to treatment each patient was examined by one of the 
emergency medicine residents or emergency department staff. 
During the initial examination the physician recorded the pres-
ence or absence of tachycardia, tachypnea, retractions, wheez-
ing, or dyspnea. Each of these clinical signs was scored with the 
absence of the sign being given a score of 0, and the presence of 
the sign being given a score of 1 (Table 1 ). An overall score was 
generated by summing these 5 individual scores. Therefore, the 
patient could receive a maximum overall score of 5 (which 
would indicate severe symptoms) and a minimum overall score 
of 0 (which would indicate mild or no symptoms). Scores 
between 0 and 5 would indicate varying degrees of pulmonary 
compromise clinically observed in each patient before and after 
treatment. This scoring system has been used in past studies 
evaluating the severity of exacerbations of asthma.7 
The patient was then given albuterol at a dosage of 0.15 mg/ 
kg per treatment. 8 The albuterol solution was mixed with normal 
saline to a total of 3.5 cc to 4.0 cc. This was placed in either an 
Acorn II Nebulizer System or a face-mask nebulizer system 
(pediatric Aerosol Mask manufactured by Hudson Oxygen 
Therapy Sales Co) and powered by 100% oxygen at 6 L!min. 
The face mask system was used for younger patients who might 
not understand the proper use of a standard nebulizer system. 
The nebulizer treatments were given at approximately 20-
minute intervals. Patients received up to 4 treatments or until 
their clinical findings had improved. At the discretion of the 
treating physician, patients could also receive oral or intrave-
nous steroids during treatment in the emergency department. 
Prior to disposition, and at least 30 minutes after the last 
nebulizer treatment, the physician rescored the patient and a 
final SaO was recorded. This time interval was used to ensure 
that the us~ of oxygen as a driving gas in the nebulizer would not 
affect our saturation measurements. 
The mean and standard deviations for age, clinical score, and 
SaO were calculated. The change in overall clinical score 
befoie and after treatment and the change in Sa02 before and 
after treatment were analyzed using the paired t-test. The change 
in each clinical sign before and after treatment was analyzed by 
the McNemar test for correlate proportions. Effects with p-
values ofless than 0.05 were considered statistically significant. 
Standard measures of diagnostic accuracy (sensitivity, specific-
Table 1.-Ciinical scoring system 
Average respiratory rates and standard deviations.'2 
Clinical Parameter Score=O Score=1 
Heart rate > 120 beats/minute > 120 beats/minute 
Respiratory rate > 2 standard deveations for age > standard deviations for age 
Dyspnea Absent or mild Moderate or severe 
Accessory muscle Absent or sub-costal Intercostal and/or 
use (retractions) retractions only supraclavicular retractions 
Wheezing Absent or end expiratory only Throughout expiration 
or expiratory and inspiratory 
-
ity, positive predictive value, negative predictive value) were 
calculated. 
Results 
Of the 82 patients entered in the study, 79 were treated by 
second-year or third-year emergency medicine residents or 
emergency department staff. The investigators (third year emer-
gency medicine residents) treated 46 of the patients. 
The mean age of the participants was 6.0+/-3.5 years. The 
overall score improved (ie, decreased) after treatment by a mean 
of 1.9+/-1.5 (Table 2). Of the 5 clinical signs scored, all im-
proved after treatment except tachycardia (Table 3). The aver-
age Sa02 for all patients improved (ie, increased) by 1.3+/-2.4% (Table 2). 
The patients were then divided into 2 groups based on their 
initial Sa02 on presentation. Patients with a pretreatment 
Sa02<95% were placed in one ~roup and those with a pretreat-
ment Sa02>95% were placed m the other group. Of the 54 
patients whose pretreatment Sa02<95%, 46 had an improve-
ment in their overall score of at least 1.0 following treatment (Fig 
1). The mean improvement in score for these 46 patients was 
2.5+/-1.1 (Table 2). Again, all clinical signs in this group 
improved following treatment except tachycardia (Table 3). Of 
the 46 patients with an improved score, 40 showed improvement 
in their Sa02 after treatment by at least 1.0% (Fig 1). The mean 
change in SaO for all46 patients was 2.6+/-2.1% (Table 2). 2 . • 
Eight patients with a pretreatment Sa02 <95% did not Improve 
their clinical score following treatment (Fig 1). None of the 
clinical signs changed significantly after treatment (Table 2). As 
a group, the Sa02 decreased by a mean of 1.1 +/-1.9%, but this 
was not significant (P = 0.14) (Table 2). Of these 8 patients, only 
one had an improved Sa02 after treatment (Fig 1 ). 
For those patients with an initial Sa02 <95%, the sensitivity 
and positive predictive value for improvement in Sa02 after 
treatment reflecting clinical improvement were 87% and 98% 
respectively. The specificity and negative predictive value were 
88% and 54%. 
Of the 28 patients whose pretreatment Sa02 >95%, 21 had an 
improved overall score after treatment (Fig 2). The mean in-
crease was 2.3+/-1.1 (Table 2). All clinical signs improved after 
treatment except tachycardia (Table 3). There was no change in 
Sa02• Seven patients with a pretreatment Sa02 >95% had no 
improvement in their overall clinical score (Fig 2). None of the 
clinical signs changed significantly, and there was no change in 
Sa02' 
Discussion 
Studies investigating changes in Sa02 shortly after initiating 
treatment with inhaled bronchodilators found that SaO)nitially 
decreases. Tal et al recorded Sa02 before, during, and after 
treatment with inhaled albuterol and intravenous aminophylline 
in 18 patients from 3 months to 20 years of age with acute 
exacerbations of asthma. The Sa02 initially decreased after 
beginning treatment and returned to pretreatment levels ap-
proximately 30 minutes after the initiation of therapy. No 
significant increases in Sa02 were noted at any time after 
treatment regardless of whether the patient was admitted or 
discharged. 5 In 28 adults with asthma, Hedges et al noted similar 
changes in Sa02 after inhaled metaproteranol.
9 Neither study 
compared the change in SaO with changes in clinical signs. 
The initial decrease in SaO:after treatment with inhaled beta-
2 agonists is thought to be the result of increased ventilation! 
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perfusion mismatching in the lungs.5·9 Because these medica-
tions initially stimulate vasodilation of the pulmonary vascular 
bed, there is increased perfusion of poorly ventilated areas of the 
lung which decreases Sa02• Subsequent bronchodilation in-
creases Sa02and alleviates the patient's respiratory distress. The 
overall effect on measured Sa02 after treatment with inhaled 
beta-2 agonists is an initial decrease followed by an increase as 
bronchospasm is reversed. The time course for Sa02 changes from beginning of the treatment to bronchodilation and in-
creased Sa02 is approximately 20 to 30 minutes.5 
Studies that measured Sa0220 to 30 minutes after the initiation 
of therapy found no significant change from pretreatment levels 
regardless of clinical response. 5•7•10 In 200 children with asthma 
who were treated with inhaled albuterol, Karem et al compared 
the change in Sa02 30 minutes after treatment between patients 
who were admitted and discharged. Discharged patients had no 
improvement in Sa02 after treatment, while those who were 
admitted showed a small, insignificant increase. In 43 children 
less than 2 years of age with wheezing-related illnesses, Bentur 
et al compared the change in a clinical scoring system to the 
change in Sa02 30 minutes after treatment. Although the clinical 
score improved following treatment, the Sa02 did not change 
significant! y. 10 
However, Yamamoto et al in looking at a large population of 
pediatric patients with wheezing found statistically significant 
increases in Sa02 following treatment with inhaled albuterol in 
patients whose pretreatment Sa02 was low. Patients with higher 
pretreatment Sa02 measurements did not show significant in-
creases in Sa02 after treatment.6 Changes in Sa02 were not 
compared to changes in clinical signs. 
In our study, patients with an initial Sa02 of <95% were placed 
into one group and those with an initial Sa02>95% into a second group. This division is based on the non-linear relationship 
between oxygen tension and Sa02• Oxygen tension can be 
considered to reflect the degree of hypoxemia, and thus the 
severity of respiratory distress. At Sa02 levels >95%, the oxyhe-
moglobin dissociation curve is flat, so oxygen tension (and thus 
clinical signs) may change dramatically with little change in the 
Sa02• For Sa02 levels <95%, the oxyhemoglobin dissociation 
curve is steeper, and changes in oxygen tension and clinical 
signs are reflected by changes in Sa02• 11 
We compared the change in Sa02 after treatment with the 
change in a clinical scoring system used in previous studies.7•10 
This scoring system is composed of 5 clinical signs associated 
with exacerbations of asthma. Assessment for the presence of 
these signs is not dependent on patient compliance and is easily 
accomplished at the bedside. The usefulness of this system in 
predicting the need to admit pediatric patients with asthma has 
been validated.9 In our study, for patients who were judged to 
respond to treatment, there was improvement in all clinical signs 
except heart rate. The absence of change in heart rate is likely 
due to albuterol causing either a beta-2-stimulated vasodilation 
and reflex tachycardia or direct beta-1 stimulation of the heart. 5 
Therefore, changes in heart rate should not be used in the 
assessment of clinical response to treatment with nebulized 
albuterol, and it should be removed from clinical scoring sys-
tems evaluating the response to beta-2 agonists in the future. 
The results of this study show that for children with asthma 
who have an initial Sa02<95%, improvement in Sa02 after 
treatment with inhaled albuterol is a strong predictor of clinical 
improvement (PPV=98% ). Although an increase in Sa02 of 1% is accepted as significant, of the 40 patients with improved 
clinical signs and Sa02 after treatment, 33 had an increase in 
Sa02 of 2% or more (82.5% ), and 24 had an increase in Sa02 of 3% or more (60%) (Fig 3). Furthermore, it is important to recall 
that small increases in Sa02 on the steep portion of the oxyhemo-
globin dissociation curve represent significant increases in 
oxygen tension and relief of hypoxemia. 
For patients with an initial Sa02 <95%, the negative predictive 
value for lack of improvement in Sa02 after treatment indicating 
no clinical improvement is low (54%). Therefore, these patients 
require further evaluation to determine their medical needs. Of 
the 13 patients in our study with an initial Sa02 <95% who did not have an improvement in Sa02 after treatment, the clinical 
response to treatment and eventually disposition of these pa-
tients varied considerably. Five patients showed considerable 
deterioration in their clinical scores and were admitted. Eight 
patients were discharged home, but only 5 had improvements in 
their clinical scores. 
Regardless of the clinical response to inhaled albuterol, pa-
tients with initial Sa02>95% did not have significant changes in 
Sa02• Lack of improved Sa02 after treatment with inhaled 
Table 2.-clinical scores and Sa02 before and after treatment, as well as change in clinical score and Sa02 with calculated p-values 
after treatment. 
Before 
No. Age Treatment 
Score 
All Patients 82 6.0 3.1 
+/-3.5 +1-1.6 
Initial Sa02:>95% 46 5.9 3.7 
and Clinical +/-3.2 +1-1.3 
Improvement 
Initial Sa02:>95% 8 7.3 2.5 
and No Clinical +1-2.3 +1-2.0 
Improvement 
Initial Sa0,>95% 21 5.3 2.9 
and Clinical +I- 3.8 +1-1.4 
Improvement 
lntital Sa02>95% 7 7.0 1.3 
and No Clinical +1-4.5 +1-1.8 
Improvement 
Before After After 
Treatment Treatment Treatment 
SaO, Score SaO, 
94.7 1.2 96.0 
+1-2.3 + /-1.4 + 1- 2.4 
93.4 1.2 96.0 
+ 1- 1.8 +1-1.1 +1-2.1 
94.0 2.9 92.9 
+/-2.1 +/-2.3 +1-3.6 
97.0 0.5 97.1 
+I- 0.9 +1-0.6 +1-1.7 
97.4 1.4 96.7 
+/-1.0 +1-1.8 + /-1.6 
-
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Change P-value of Change in P-valueof 
in score Change in SaO, Change in 
Score sao, 
1.9 <.0001 1.3 <.0001 
+1-1.5 +I- 2.4 
2.5 2.6 
+1-1.1 <.0001 +/-2.1 <.0001 
-0.5 0.10 -1.1 0.14 
+1-0.8 +/-1.9 
2.3 <.0001 0.2 0.61 
+ /-1.1 +/-1.7 
-0.1 0.36 -0.7 0.18 
+1-.0.4 + /-1.3 
albuterol did not indicate lack of clinical response to treatment; 
therefore, changes in Sa02 after treatment for this group of 
patients has little utility. 
Conclusion 
This study demonstrates that for pediatric asthma patients 
with an initial Sa02<95%, increased Sa02 after treatment with 
inhaled albuterol is predictive of clinical improvement. Failure 
to improve Sa02 after treatment is not predictive of lack of 
clinical improvement, and further evaluation is required for 
appropriate disposition. In patients with an initial Sa02>95%, 
changes in Sa02 after treatment with inhaled albuterol are not 
indicative of clinical response. An understanding of the changes 
in Sa02 in pediatric asthma patients following inhaled albuterol 
combined with appropriate clinical evaluation can facilitate the 
disposition of these patients. 
Fig 1.--Piot of change in score versus change in SaO 2 after treatment with inhaled albuterol for 
patients with intitial Sa02~95%. 
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Fig 2.--Piot of change in score versus change in SaO 2 after treatment with inhaled albuterol for 
patients with initial Sa02~95%. 
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Table 3.-Percentage Change and Calculated p-values of Clinical Signs after Treatment with Inhaled Albuterol. 
No. Change P-value 
in HR of Change 
in HR 
All Patients 82 t1% 1.00 
Initial SA02$;95% 46 -5% 0.75 
and Clinical 
Improvement 
Initial Sa0,~95% 8 +58% 0.06 
and No Clinical 
Improvement 
Initial Sa02>95% 21 ·9% 0.62 
and Clinical 
Improvement 
Initial Sa02>95% 7 0% 1.00 
and No Clinical 
Improvement 
Change P-value Change P-value 
in RR of Change in DYS of Change 
inRR inDYS 
·37% <.0001 -44% <.0001 
-51% <.0001 -54% <.0001 
-13% 1.00 +12% 1.00 
-52% <.001 ·57% <.001 
+15% 1.00 0% 1.00 
-
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Change P-value Change P-value 
in RET of Change inWZ of Change 
in RET inWZ 
-49% <.0001 ·67% <.0001 
-69% <.0001 -80% <.0001 
0% 1.00 ·25% 0.50 
-38% <.01 -76% <.0001 
0% 1.00 0% 1.00 
